These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34796892)

  • 1. Comparative reactivity of medicinal gold(I) compounds with the cyclic peptide vasopressin and its diselenide analogue.
    Lamarche J; Alcoceba Álvarez E; Cordeau E; Enjalbal C; Massai L; Messori L; Lobinski R; Ronga L
    Dalton Trans; 2021 Dec; 50(47):17487-17490. PubMed ID: 34796892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conivaptan therapy in an infant with severe hyponatremia and congestive heart failure.
    Sahu R; Balaguru D; Thapar V; Haque I; Pham-Peyton C; Bricker JT
    Tex Heart Inst J; 2012; 39(5):724-6. PubMed ID: 23109779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the effects of the vasopressin V2 receptor on sweating, fluid balance, and performance during exercise.
    Hew-Butler T; Hummel J; Rider BC; Verbalis JG
    Am J Physiol Regul Integr Comp Physiol; 2014 Aug; 307(4):R366-75. PubMed ID: 24944242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin and alcohol: a multifaceted relationship.
    Harper KM; Knapp DJ; Criswell HE; Breese GR
    Psychopharmacology (Berl); 2018 Dec; 235(12):3363-3379. PubMed ID: 30392132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gold-Promoted Biocompatible Selenium Arylation of Small Molecules, Peptides and Proteins.
    Nakahata DH; Kanavos I; Zubiria-Ulacia M; Inague A; Salassa L; Lobinski R; Miyamoto S; Matxain JM; Ronga L; de Paiva REF
    Chemistry; 2024 Mar; 30(15):e202304050. PubMed ID: 38197477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The pathway of vasopressin as a pharmacological target in nephrology: a narrative review].
    Recupero M; Fulignati P; Naticchia A; D'Alonzo S; D'Ascenzo F; Costanzi S
    G Ital Nefrol; 2018 Dec; 35(6):. PubMed ID: 30550035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The electrochemical profiles of Auranofin and Aubipy
    Kupiec M; Ziółkowski R; Massai L; Messori L; Pawlak K
    J Inorg Biochem; 2019 Sep; 198():110714. PubMed ID: 31170580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles.
    Massai L; Cirri D; Michelucci E; Bartoli G; Guerri A; Cinellu MA; Cocco F; Gabbiani C; Messori L
    Biometals; 2016 Oct; 29(5):863-72. PubMed ID: 27476157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine vasopressin antagonism in heart failure: Current status and possible new directions.
    Goldsmith SR
    J Cardiol; 2019 Jul; 74(1):49-52. PubMed ID: 30904236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability.
    Gabbiani C; Casini A; Kelter G; Cocco F; Cinellu MA; Fiebig HH; Messori L
    Metallomics; 2011 Dec; 3(12):1318-23. PubMed ID: 21887452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical biology of anticancer gold(III) and gold(I) complexes.
    Zou T; Lum CT; Lok CN; Zhang JJ; Che CM
    Chem Soc Rev; 2015 Dec; 44(24):8786-801. PubMed ID: 25868756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hormone-binding site of neurophysins: binding of vasopressin to the N-terminal sub-domain dissected from human MSEL-neurophysin through endopeptidase Lys-C.
    Michel G; Chauvet J; Acher R
    Neuropeptides; 1991 Dec; 20(4):211-6. PubMed ID: 1812403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gold Drugs with {Au(PPh
    Stenger-Smith JR; Mascharak PK
    ChemMedChem; 2020 Nov; 15(22):2136-2145. PubMed ID: 33025735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurophysin binding of vasopressin analogues altered at the NH 2 - and COOH-terminal positions.
    Kluh I; Sedláková E; Barth T; Cort JH
    Mol Pharmacol; 1973 May; 9(3):414-20. PubMed ID: 4710138
    [No Abstract]   [Full Text] [Related]  

  • 15. Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand.
    Maiore L; Cinellu MA; Michelucci E; Moneti G; Nobili S; Landini I; Mini E; Guerri A; Gabbiani C; Messori L
    J Inorg Biochem; 2011 Mar; 105(3):348-55. PubMed ID: 21421122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of Gold Candidates against Human Colon Cancer.
    Abbasi M; Yaqoob M; Haque RA; Iqbal MA
    Mini Rev Med Chem; 2021; 21(1):69-78. PubMed ID: 32767935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects.
    Shoaf SE; Wang Z; Bricmont P; Mallikaarjun S
    J Clin Pharmacol; 2007 Dec; 47(12):1498-507. PubMed ID: 17925589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotoxicity of organoselenium compounds in human leukocytes in vitro.
    Santos DB; Schiar VP; Ribeiro MC; Schwab RS; Meinerz DF; Allebrandt J; Rocha JB; Nogueira CW; Aschner M; Barbosa NB
    Mutat Res; 2009 May; 676(1-2):21-6. PubMed ID: 19486860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-resolved study on the reactions of organic selenides with hydroxyl and oxide radicals, hydrated electrons, and H-atoms in aqueous solution, and DFT calculations of transients in comparison with sulfur analogues.
    Tobien T; Bonifacić M; Naumov S; Asmus KD
    Phys Chem Chem Phys; 2010 Jul; 12(25):6750-8. PubMed ID: 20431832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: solution behavior, reactions with model proteins, antiproliferative properties.
    Maiore L; Cinellu MA; Nobili S; Landini I; Mini E; Gabbiani C; Messori L
    J Inorg Biochem; 2012 Mar; 108():123-7. PubMed ID: 22173093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.